OOIR: Observatory of International Research

Papers

(The H4-Index of JNCI-Journal of the National Cancer Institute is 42. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2022-08-01 to 2026-08-01.)

Article	Citations
Correction to: ATM Germline-Mutated Gastroesophageal Junction Adenocarcinomas: Clinical Descriptors, Molecular Characteristics, and Potential Therapeutic Implications	264
Vertical integration in oncology: what does it mean for patients with cancer?	190
Re: Deng and Heybati	147
Response to Liu and Zhang	140
Factors associated with timely COVID-19 vaccination in a population-based cohort of patients with cancer	114
Evaluating a blood test for colon cancer screening: how simulation modeling can inform clinical policy making and research	95
Pre- and post-diagnostic use of antihypertensive medications and stage I-III colorectal cancer survival: prospective cohort study	92
Independent associations between obesity, glucose metabolism, and breast cancer risk through unrelated pathways	88
Discovering plasma proteins associated with breast cancer incidence in postmenopausal women in the Atherosclerosis Risk in Communities study	85
Mediators of Racial Disparities in Heart Dose Among Whole Breast Radiotherapy Patients	79
RE: Exploring the cross-cancer effect of circulating proteins and discovering potential intervention targets for 13 site-specific cancers	78
The National Cancer Institute clinical trials planning meeting to address gaps in observational and intervention trials for cancer-related cognitive impairment	76
Method of primary breast cancer detection and the disease-free interval, adjusting for lead time	74
RE: Use of artificial intelligence for cancer clinical trial enrollment	73
Rare cancers research: current state of knowledge and emerging opportunities for prevention and interception	72
The impact of HIV on cervical cancer elimination in KwaZulu-Natal: a comparative modeling analysis	68
Addressing Diversity, Equity, and Inclusion at the JNCI Journals	67
Systematic investigation of genetically determined plasma and urinary metabolites to discover potential interventional targets for colorectal cancer	67
Understanding risk factors for endometrial cancer in young women	63
Dyslipidemia and cardiovascular disease among childhood cancer survivors: a St. Jude Lifetime Cohort report	62
Race and clinical outcomes in hormone receptor-positive, HER2-negative, node-positive breast cancer in the randomized RxPONDER trial	59
Incorporation of patient-reported outcomes in pediatric cancer clinical trials: design, implementation, and dissemination	56
Metabolically (un)healthy obesity and risk of obesity-related cancers: a pooled study	56
Re: Cardiovascular disease risk after radiotherapy and anthracycline-based chemotherapy for diffuse large B-cell lymphoma	54
The National Cancer Policy Forum: a strong voice for improving cancer care and outcomes	54

Ethylene oxide emissions and incident breast cancer and non-Hodgkin lymphoma in a US cohort	53
Long-term aspirin use and cancer risk: a 20-year cohort study	52
Cancer prevention in context: interplay of perceived discrimination, neighborhood deprivation, and cancer-related risk and protective factors	52
Association between smoking habits and breast density, changes in breast density, and breast cancer in Asian women	52
Circulating pre-diagnostic metabolites and risk of hepatocellular carcinoma and intrahepatic cholangiocarcinoma: a population-based study of 12 cohorts	52
Increasing diversity in clinical trials: demographic trends at the National Cancer Institute, 2005-2020	51
Joint associations of accelerometer-measured physical activity and cardiovascular-kidney-metabolic syndrome stages with the risks of cancer and all-cause mortality	50
Survivorship after adolescent and young adult cancer: models of care, disparities, and opportunities	50
RE: Prevalence of cancer survivors in the United States	49
Association of common genetic alterations with tumor recurrence in papillary thyroid cancer	49
Reduced adipose tissue with limited loss of lean mass after weight loss: results from the Prostate Cancer Active Lifestyle Study	49
RE: Autoimmune disease and the risk of anal cancer in the US elderly population	48
Combining antivascular endothelial growth factor and anti-epidermal growth factor receptor antibodies: randomized phase II study of irinotecan and cetuximab with/without ramucirumab in second-line col	47
Cancer control co-benefits of the climate-related provisions in the American Inflation Reduction Act	46
Correction to: Obesity-Specific Improvement of Lung Cancer Outcomes and Immunotherapy Efficacy with Metformin	46
Correction to: Quality of Life in Older Adults After Major Cancer Surgery: The GOSAFE International Study	45
Treatment deescalation for older women with favorable breast cancers: patient values and shared decision making	44
Association between racialized economic segregation and stage at diagnosis for 3 screenable cancers in New York City	42
Landscape of somatic genetic alterations and PAM50 intrinsic subtypes in breast cancer associated with germline pathogenic variants in DNA-repair genes	42
Toxicity risk score and clinical decline after adjuvant chemotherapy in older breast cancer survivors	42